医学
认知障碍
Pet成像
疾病
内科学
预测值
阿尔茨海默病
正电子发射断层摄影术
核医学
作者
Darren M. Weber,Steven W. Taylor,Robert Lagier,Jueun C Kim,Scott Goldman,Nigel J. Clarke,David E. Vaillancourt,Ranjan Duara,Karen N. McFarland,Wei‐en Wang,Todd E. Golde,Michael K. Racke
标识
DOI:10.3389/fneur.2024.1364658
摘要
Introduction Plasma Aβ42/40 ratio can help predict amyloid PET status, but its clinical utility in Alzheimer’s disease (AD) assessment is unclear. Methods Aβ42/40 ratio was measured by LC-MS/MS for 250 specimens with associated amyloid PET imaging, diagnosis, and demographic data, and for 6,192 consecutive clinical specimens submitted for Aβ42/40 testing. Results High diagnostic sensitivity and negative predictive value (NPV) for Aβ-PET positivity were observed, consistent with the clinical performance of other plasma LC-MS/MS assays, but with greater separation between Aβ42/40 values for individuals with positive vs. negative Aβ-PET results. Assuming a moderate prevalence of Aβ-PET positivity, a cutpoint was identified with 99% NPV, which could help predict that AD is likely not the cause of patients’ cognitive impairment and help reduce PET evaluation by about 40%. Conclusion High-throughput plasma Aβ42/40 LC-MS/MS assays can help identify patients with low likelihood of AD pathology, which can reduce PET evaluations, allowing for cost savings.
科研通智能强力驱动
Strongly Powered by AbleSci AI